Source comparison
Selank Comparison: Anxiolytic Peptides and Mechanisms
Selank belongs to a broader class of synthetic anxiolytic and nootropic peptides developed through rational modification of endogenous regulatory peptides. Understanding how Selank compares to structurally and mechanistically related compounds clarifies its di
This comparison does not assign a generated winner or score.
- Selank belongs to a broader class of synthetic anxiolytic and nootropic peptides developed through rational modification of endogenous regulatory peptides. Understanding how Selank compares to structurally and mechanistically related compounds clarifies its distinct profile.
- Selank
- BDNF upregulation, IL-6 modulation, enkephalin stabilization
- Intranasal
- ~25 minutes
- None observed
- Anxiolytic without sedation or tolerance; intranasal delivery achieves CNS penetration without injection
- Semax
- BDNF upregulation, NGF modulation, acetylcholine enhancement
- ~20 minutes
- Cognitive enhancer with mild stimulant profile; structurally related to ACTH but lacks hormonal effects
- Noopept
- AMPA receptor potentiation, NGF/BDNF expression
- Oral
- ~25 minutes (active metabolites persist 60+ min)
- Racetam-like cognitive enhancer; requires higher oral doses than Selank for comparable effect
- Diazepam
- Direct GABA-A receptor agonism
- 20–100 hours (including metabolites)
- High
- Gold-standard anxiolytic with sedation, amnesia, tolerance, and withdrawal profile
- Phenibut
- GABA-B receptor agonism
- ~5 hours
- Moderate to high
- Produces anxiolysis and sedation; rapid tolerance development and withdrawal symptoms reported
- Selank and Semax are structurally related but mechanistically distinct. Semax is derived from ACTH (adrenocorticotropic hormone) fragments and demonstrates stronger cognitive-enhancing and stimulatory effects, while Selank's tuftsin-derived structure confers anxiolytic and immunomodulatory properties. Both peptides share intranasal administration, high CNS bioavailability, and absence of tolerance or dependence risk. Characteristics that distinguish them from conventional anxiolytics.
- Noopept, a synthetic peptide mimic of piracetam, operates through glutamatergic modulation rather than monoamine or cytokine pathways. While both Selank and Noopept increase BDNF expression, Noopept's primary mechanism involves AMPA receptor potentiation, producing cognitive enhancement with a more stimulant-like subjective profile. Selank's anxiolytic effects are more pronounced than Noopept's, making the two compounds complementary rather than interchangeable in research contexts.
- Direct comparison to GABA receptor modulators highlights Selank's mechanistic novelty. Benzodiazepines like diazepam produce rapid, robust anxiolysis through allosteric enhancement of GABA-A receptor chloride conductance, but this mechanism inherently produces sedation, cognitive impairment, and tolerance. Selank achieves anxiolytic effects without direct GABAergic action, explaining why it lacks these side effects. This makes Selank a valuable research tool for studying anxiety mechanisms independent of GABA-A modulation.